Randall J. Olson, MD

While there are currently no FDA-approved pharmacological therapies for the treatment of cataracts, an eye drop demonstrated promising vision improvements in patients with early-stage cataracts in a phase 1/2 clinical trial.

In this episode, Susan M. MacDonald, MD, and Laura B. Enyedi, MD, talk with Randall J. Olson, MD, William Trattler, MD, David F. Chang, MD, and Thomas A. Oetting, MS, MD, about the importance of providing mentorship, advocacy and leadership opportunities to women in ophthalmology.

Endophthalmitis cases in a large retrospective clinical cohort study of patients who underwent cataract surgery were related to organism resistance in cefuroxime-treated eyes and sensitive organisms in moxifloxacin-treated eyes.

KOLOA, Hawaii — At Hawaiian Eye 2020, Randall J. Olson, MD, CEO and chair of the John A. Moran Eye Center at the University of Utah, gives his presentation on the latest strategies to prevent endophthalmitis following cataract surgery.

KOLOA, Hawaii — At Hawaiian Eye 2020, Randall J. Olson, MD, CEO of Moran Eye Center, addresses core principles he discussed in his presentation on endophthalmitis. Olson said monitoring incidence as well as making precise incisions to prevent wound leakage are some of the methods to reduce the risk for endophthalmitis.

Randall J. Olson, MD, at Hawaiian Eye 2017.

Intracameral injection of antibiotics as endophthalmitis prophylaxis in cataract surgery has been much discussed since the publication of a major study funded by the European Society of Cataract and Refractive Surgeons. That study concluded an intracameral injection of cefuroxime at the time of cataract surgery reduced the risk for developing endophthalmitis postoperatively. 1

BAK is a powerful antifungal and antibacterial preservative with broad-spectrum activity against microorganisms. —Randall J. Olson, MD

When selecting topical anti-infective medications for treatment of infection or for surgical prophylaxis, clinicians must consider the risk-benefit ratio. The available evidence demonstrates that increasing the concentration of active drug does not necessarily increase efficacy but may decrease ocular tolerability and safety and inhibit wound healing.